Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR-TKIs Resistance

Overview

Journal Clin Respir J

Specialty Pulmonary Medicine

Date 2024 Dec 4

PMID 39631794

Authors

Jin Tian

Zhiqi Shi

Lili Zhao

Peng Liu

Xiaojun Sun

Lin Long

Jianhua Zang

Jun Xiao

Affiliations

Soon will be listed here.

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment choice for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. EGFR-TKIs have made significant progress in the treatment of advanced NSCLC patients, but drug resistance issues still inevitably arise. The mechanism of drug resistance and subsequent treatment has been current research challenge and priority. Immune checkpoint inhibitors (ICIs) are a new choice for late-stage NSCLC patients without druggable molecular alterations. Currently, several studies have applied ICIs therapy for NSCLC patients with EGFR-TKIs resistance and explored the potential efficacy of ICIs. This review elaborates on the current status of immunotherapy after EGFR-TKIs resistance, including ICIs monotherapy, combined with EGFR-TKIs, chemotherapy, antiangiogenic drugs, and other therapies.

References

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Reck M, Mok T, Nishio M, Jotte R, Cappuzzo F, Orlandi F . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019; 7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0. View

Gettinger S, Hellmann M, Chow L, Borghaei H, Antonia S, Brahmer J . Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. J Thorac Oncol. 2018; 13(9):1363-1372. DOI: 10.1016/j.jtho.2018.05.015. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Izumi M, Ogawa K . Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer. Cancer Sci. 2019; 110(10):3244-3254. PMC: 6778652. DOI: 10.1111/cas.14156. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Zhou C, Wang Z, Fu C, Tao H, Liu C . The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study. Ann Transl Med. 2023; 11(3):157. PMC: 9951015. DOI: 10.21037/atm-22-6272. View

Du W, Zhu J, Zeng Y, Liu T, Zhang Y, Cai T . KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway. Cell Death Differ. 2020; 28(4):1284-1300. PMC: 8027631. DOI: 10.1038/s41418-020-00651-5. View

Huang H, Zhu X, Yu Y, Li Z, Yang Y, Xia L . EGFR mutations induce the suppression of CD8 T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer. J Transl Med. 2024; 22(1):653. PMC: 11246587. DOI: 10.1186/s12967-024-05456-5. View

10.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K . Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017; 28(7):1532-1539. DOI: 10.1093/annonc/mdx183. View

11.

Combes A, Samad B, Tsui J, Chew N, Yan P, Reeder G . Discovering dominant tumor immune archetypes in a pan-cancer census. Cell. 2021; 185(1):184-203.e19. PMC: 8862608. DOI: 10.1016/j.cell.2021.12.004. View

12.

Oliver A . Lung Cancer: Epidemiology and Screening. Surg Clin North Am. 2022; 102(3):335-344. DOI: 10.1016/j.suc.2021.12.001. View

13.

Herbst R, Wu Y, John T, Grohe C, Majem M, Wang J . Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023; 41(10):1830-1840. PMC: 10082285. DOI: 10.1200/JCO.22.02186. View

14.

Liu W, Wang L, Zhou F, Liu S, Wang W, Zhao E . Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC. Drug Resist Updat. 2023; 70:100987. DOI: 10.1016/j.drup.2023.100987. View

15.

Gao Y, Nihira N, Bu X, Chu C, Zhang J, Kolodziejczyk A . Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020; 22(9):1064-1075. PMC: 7484128. DOI: 10.1038/s41556-020-0562-4. View

16.

Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X . Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021; 22(9):1265-1274. DOI: 10.1016/S1470-2045(21)00333-8. View

17.

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

18.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

19.

Oshima Y, Tanimoto T, Yuji K, Tojo A . EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(8):1112-1115. PMC: 5885195. DOI: 10.1001/jamaoncol.2017.4526. View

20.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View